PTCH1 and neoplasm: LDE225 (N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide) belongs to a class of biphenyl carboxamides and has been identified as a SMO antagonist able to bind its transmembrane domain (TMD) and to reduce tumor growth of both subcutaneous and subcortically orthotopic mice models implanted with Ptch+/−;p53−/− MB cells.